|
| Press Releases |
|
 |
|
| Friday, March 31, 2023 |
|
|
Eisai: Additional Detailed Analyses from Phase 2 Study 201 of Lecanemab Published as Three Papers in Peer-Reviewed Journals |
| Eisai Co., Ltd. and Biogen Inc. announced today that three additional detailed analyses from the Phase IIb clinical study (Study 201), evaluating the efficacy and safety of lecanemab for mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and mild AD (collectively known as early AD), were published in the peer-reviewed journals. more info >> |
|
| Friday, March 24, 2023 |
|
|
Eisai to Present Research from Oncology Portfolio at The Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women's Cancer |
| Eisai Co., Ltd. announced today the presentation of two abstracts at the Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women's Cancer (#SGOMtg), which is taking place in-person in Tampa, Florida and virtually from March 25-28. more info >> |
|
| Thursday, March 23, 2023 |
|
|
Eisai to Present New Lecanemab Data, Including Research Evaluating Safety Profile, Clinical Outcomes and Quality of Life Measures, as Well as Other Important Alzheimer's Disease Research, at the AD/PD 2023 Annual Meeting |
| Eisai Co., Ltd. announced today the company will present the latest findings on lecanemab (generic name, U.S. brand name: LEQEMBI), Eisai's anti-amyloid beta (Aβ) protofibril* antibody for the treatment of Alzheimer's disease (AD), at the 2023 International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders (AD/PD). more info >> |
|
| Monday, March 20, 2023 |
|
|
Eisai Publishes Societal Value of Lecanemab Using Phase 3 Clarity AD Data in Peer-Reviewed Neurology and Therapy Journal |
| Eisai Co., Ltd. today announced the publication of updated results from an evaluation estimating the societal value of anti-amyloid-beta (Aβ) protofibril antibody lecanemab (generic name, U.S. brand name: LEQEMBI) in people living with mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and mild AD (collectively known as early AD). more info >> |
|
| Tuesday, March 14, 2023 |
|
|
U.S. Veterans' Health Administration (VHA) Provides Coverage of LEQEMBI (lecanemab-Irmb) Two Months After LEQEMBI's FDA Accelerated Approval for Veterans Living with Early Stages of Alzheimer's Disease |
| Eisai Co., Ltd. announced today that the U.S. Veterans' Health Administration (VHA) is providing coverage of LEQEMBI (lecanemab-irmb) to veterans living with early stages of Alzheimer's disease (AD). VHA healthcare professionals meeting the criteria set forth by the VHA can prescribe LEQEMBI to veterans who fit the VHA's criteria and the U.S. Food and Drug Administration's (FDA) current label. more info >> |
|
| Friday, March 10, 2023 |
|
|
Eisai Receives the "Basic Achievement Grand Prize" at the 2023 J-Win Diversity Award |
| Eisai Co., Ltd. announced today that it was selected as the winner of the "Basic Achievement Grand Prize" at the "2023 J-Win Diversity Award" held by non-profit organization Japan Women's Innovative Network (NPO J-Win). more info >> |
|
| Thursday, March 9, 2023 |
|
|
Eisai Certified as a 2023 Health and Productivity Management Outstanding |
| Eisai Co., Ltd. announced today that it has been certified as a Health and Productivity Management Outstanding Organization in the large enterprise category (White 500) by Japan's Ministry of Economy, Trade and Industry and the Nippon Kenko Kaigi. more info >> |
|
| Monday, March 6, 2023 |
|
|
FDA Accepts Eisai's Filing of a Supplemental Biologics License Application and Grants Priority Review for Traditional Approval of LEQEMBITM (lecanemab-irmb) for the Treatment of Alzheimer's Disease |
| Eisai Co., Ltd. and Biogen Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted Eisai's supplemental Biologics License Application (sBLA) for LEQEMBITM (lecanemab-irmb) 100 mg/mL injection for intravenous use, supporting the conversion of the accelerated approval of LEQEMBI to a traditional approval. more info >> |
|
| Thursday, March 2, 2023 |
|
|
Biogen Japan and Eisai Provide Update on Co-Promotion Of Multiple Sclerosis Treatments In Japan |
| Biogen Japan Ltd. and Eisai Co., Ltd. announced today the termination of the co-promotion agreement that has been in place since January 2018 for Biogen Japan's multiple sclerosis (MS) treatments TECFIDERA (dimethyl fumarate), TYSABRI (natalizumab, genetic recombinant) and AVONEX (interferon beta 1a, genetic recombinant) in Japan as of March 31, 2023. more info >> |
|
| Tuesday, February 28, 2023 |
|
|
Biologics License Application for Lecanemab Designated for Priority Review by China National Medical Products Administration |
| Eisai Co., Ltd. and Biogen Inc. announced today that the Biologics License Application (BLA) for lecanemab, an investigational anti-amyloid beta (Abeta) protofibril antibody, has been designated for Priority Review by the National Medical Products Administration (NMPA) in China. more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
Wasion Holdings Subsidiaries Secure Over HK$253 Million in Contracts from State Grid's 2025 First Metering Equipment Tender
Jun 2, 2025 09:43 HKT/SGT
|
|
|
TransNusa Increases Scheduled Flight Frequency to Twice Daily 
Jun 2, 2025 08:30 HKT/SGT
|
|
|
Hola Prime Launches Performance Coaching Initiative to Tackle the #1 Barrier to Trader Success: The Mind
May 30, 2025 19:00 HKT/SGT
|
|
|
Mitsubishi Corporation Establishes New Corporate Venture Capital Company
May 30, 2025 18:36 JST
|
|
|
The PropertyGuru Asia Property Awards (Middle East) return for 2025 edition with inaugural Dubai launch
May 30, 2025 14:00 HKT/SGT
|
|
|
Honda to Co-develop Refueling Port Connecting System for On-orbit Satellite Refueling with Astroscale
May 30, 2025 11:54 JST
|
|
|
IFS and NEC Strengthen their Strategic Partnership to Create New Value
May 30, 2025 10:11 JST
|
|
|
Genetec maintains profitability in Q3FY2025 on higher revenue
May 29, 2025 20:00 HKT/SGT
|
|
|
Naoris Protocol Raises $3M in Strategic Round Led by Mason Labs
May 29, 2025 19:00 HKT/SGT
|
|
|
MODONG Coffee Proudly Sponsors "G-DRAGON 2025 WORLD TOUR [Ubermensch] IN TAIPEI, presented by KGI FINANCIAL GROUP" as Official Sponsor
May 29, 2025 18:19 HKT/SGT
|
|
|
Mazda Production and Sales Results for April 2025
May 29, 2025 18:44 JST
|
|
|
Euro Manganese Closes C$11.2 million (A$12.3 million) Financing
May 29, 2025 16:09 HKT/SGT
|
|
|
First patient dosed in YK012 trial-the world's first TCE therapy for primary membranous nephropathy
May 29, 2025 15:49 HKT/SGT
|
|
|
SAPPE Makes a Global Splash in the Beverage Market, Unveils Global Campaign "Life's too Short, You Gotta Chew" at THAIFEX - ANUGA ASIA 2025
May 29, 2025 08:00 HKT/SGT
|
|
|
Global Leaders Gather for XIII International Meeting on International Cooperation
May 28, 2025 20:30 HKT/SGT
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
